


Dkt. 0392/25799-DB-Z/RDK

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Jean-Claude BYSTRYN  
U.S. Serial No. : 10/046,880  
U.S. Filing Date : January 15, 2002  
For : ANTI-CANCER VACCINE

RECEIVED  
CENTRAL FAX CENTER

SEP 04 2007



1185 Avenue of the Americas  
New York, N.Y. 10036  
September 4, 2007

SIR:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to applicants' duty of disclosure, applicants wish to call to the attention of the Examiner in charge of the above-identified application the references listed on the enclosed form PTO-1449. The Examiner is respectfully requested to review the references and make them of record in the application.

RECEIVED  
CENTRAL FAX CENTER

SEP 04 2007


Applicant : Jean-Claude BYSTRYN  
Serial No. : 10/046,880  
Filing Date : January 15, 2002  
Page 2

The Commissioner is hereby authorized to charge any fee required in connection with the filing of this Information Disclosure Statement to Deposit Account 03-3125.

Respectfully submitted,

Dated: September 4, 2007

By:



Robert D. Katz, Esq.  
Registration No. 30,141  
Cooper & Dunham LLP  
Customer No. 23432  
1185 Avenue of the Americas  
New York, New York 10036  
rkatz@cooperdunham.com  
(212) 278-0400

Attorney for Applicant

RECEIVED  
CENTRAL FAX CENTER

SEP 04 2007

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 25799-DBZ/RDK		Serial No. 10/046,880	
INFORMATION DISCLOSURE CITATION BY APPLICANT (Use several sheets if necessary)				Applicant Jean-Claude BYSTRYN, MD.		Filing Date January 15, 2002	
				Group 1643			
<b>U.S. PATENT DOCUMENTS</b>							
Examiner (Initial)	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
	A01						
	A02						
	A03						
<b>FOREIGN PATENT DOCUMENTS</b>							
	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	A04						
	A05						
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
/C.Y./	A06 Bystryn, J.-C., et al., "Immunogenicity of a Polyvalent Melanoma Antigen Vaccine in Patients with Early Melanoma," Proceedings of American Association for Cancer Research, Vol. 26; March 1985, page 312, Abstract No. 1233						
/C.Y./	A07 Bystryn, J.-C., et al., "Effects of a Polyvalent Tumor Antigen Vaccine in Human Malignant Melanoma," Clinical Research, Vol. 33; No. 2; April 1985, page 628A						
	A08						
	A09						
	A10						
	A11						
<b>EXAMINER</b> /Christopher Yaen/		03/02/2008					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Sheet 1 of 1